At first glance, SPDR S&P Biotech ETF (NYSEARCA:XBI) and Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) look like two flavors of the same bet on drug discovery. However, the structures diverge sharply. XBI spreads bets almost evenly across more than a hundred biotech names, while PBE runs a concentrated, quant-screened book anchored by large-cap incumbents. That structural gap explains why XBI has ripped 72.6% higher over the past year while PBE returned 34.7%, and why the ranking reverses in tougher markets.
What Each Fund Is Actually Betting On
XBI tracks the S&P Biotechnology Select Industry Index using a modified equal-weight rule. No single name dominates: top holding Apogee Therapeutics weighs in at 1.49%, followed by Twist Bioscience and Moderna, each at 1.41%. The top 10 combined weight is just 13.3%. The implicit bet is biotech beta: small- and mid-cap clinical-stage developers get equal footing with mega-caps, so a hot readout from a $2 billion company moves the fund almost as much as one from a $30 billion one. This amplifies gains during risk-on catalyst cycles and punishes the fund during rate shocks that starve unprofitable biotechs of capital.
PBE takes the opposite approach. Its Dynamic Biotech & Genome Intellidex screens on momentum, earnings, quality, and value, then applies tiered weights to a much shorter list. The 30-position portfolio leans more heavily on profitable incumbents: Vertex Pharmaceuticals at 5.18%, Biogen at 5.08%, and Amgen at 4.9%. PBE is effectively betting that fundamentals and quality factors beat lottery-ticket clinical bets over time.
Where the Difference Shows Up
The 2026 rebound in speculative biotech has been kind to XBI. Year to date, it is up 24.9% against PBE’s 9.1%. Over 10 years, XBI’s equal-weight tilt has produced a 156.7% total return, versus 125.7% for PBE.
Stretch the window differently and PBE’s defensive posture matters. Over the trailing five years, a period that included the brutal 2021-2022 biotech drawdown, returns were essentially the same: 20.1% for PBE versus 20.3% for XBI.
Cash, large-cap names, and a quality screen cushioned the fall while XBI’s small-cap developers were cut in half.
The Practical Comparison
| Metric | XBI | PBE |
|---|---|---|
| Methodology | Modified equal-weight | Quant Intellidex, tiered |
| Holdings | 100+ (top 10 = 13.6%) | ~30 positions (top 10 = 44.5%) |
| Top holding weight | 1.49% (Apogee) | 5.18% (Vertex) |
| Net assets | $10.7 billion | $280.3 million |
| Expense ratio | 0.35% | ~0.58% (historical) |
| YTD return | 24.9% | 9.1% |
| 5-year return | 20.3% | 20.1% |
The Verdict
For a retirement-focused investor who wants biotech exposure without severe drawdowns, PBE tends to offer the smoother structural profile. Its large-cap tilt, quality screen, and standing cash sleeve produce a smoother ride, and the five-year record shows the trade-off works when small-cap biotech breaks down. Investors chasing biotech beta, particularly those who believe the FDA approval cycle and rate-cut backdrop favor clinical-stage names, will find XBI’s equal-weight engine more powerful, and its 0.35% fee is a meaningful advantage.
What would flip the call? A sustained rate-cutting cycle plus another IPO-friendly funding window would tilt the math decisively back to XBI. A credit tightening or a run of high-profile Phase 3 failures pushes it the other direction.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks